Grail (NASDAQ: GRAL), a healthcare company focused on multi-cancer early detection, saw its shares surge more than 14% on Thursday, defying a 0.6% dip in the S&P 500. The rally followed the company’s announcement of a strategic collaboration and a $110 million equity investment from two subsidiaries of Korean tech giant Samsung, aimed at commercializing Grail’s flagship Galleri test in Asian markets.
In a move to expand its international footprint, Grail disclosed it has signed a binding letter of intent with Samsung C&T and Samsung Electronics. The partnership will focus on bringing the Galleri multi-cancer early detection (MCED) test to specific Asian markets, including South Korea, with Japan and Singapore mentioned as potential future targets.
As part of the agreement, the two Samsung units will collectively invest $110 million in Grail. The investment values Grail’s common shares at $70.50 each, granting the Samsung affiliates over 1.56 million shares.
“The investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets,” said Harpal Kumar, President of International Business and Biopharma at Grail, in a press release.
Grail’s Galleri test is a groundbreaking MCED test designed to screen for a signal shared by more than 50 types of cancer through a single blood draw. The test works by detecting cancer-derived DNA that tumors shed into the bloodstream at very early stages.
This technology addresses a significant gap in current cancer screening. While recommended early detection tests exist for only a few cancers—such as breast, cervical, colorectal, prostate, and lung—approximately 70% of cancers lack any recommended screening method. MCED tests like Galleri are thus viewed as a potential paradigm shift in oncology.
Grail has demonstrated early commercial traction, having sold 370,000 Galleri tests to date, including 45,000 in the second quarter of this year. The company’s revenue grew 35% year-over-year to $126 million in the previous year, with Q2 sales rising 21% to $34.2 million. Grail reported a strong cash position with over $600 million on hand.
However, mirroring the profile of many biotech startups, Grail is not yet profitable. The company posted a net loss of $114 million last quarter and expects to burn approximately $310 million in cash this year on ongoing research, testing, and marketing initiatives.
Despite challenges and the speculative nature of its business—with FDA premarket approval submission not expected until the first half of 2026—investor enthusiasm remains high. Grail’s stock has climbed 146% year-to-date and has more than tripled over the past 52 weeks, reflecting market optimism about its long-term potential should it secure crucial regulatory and reimbursement milestones.
